Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
November 23 2015 - 8:30AM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced the appointment of Michael J. Parini to the role of
Executive Vice President and Chief Legal Officer. Mr. Parini will
serve as a member of Vertex’s Executive Committee, reporting
directly to Jeffrey Leiden, M.D., Ph.D., Vertex's Chairman,
President and Chief Executive Officer. Mr. Parini will begin his
role with Vertex effective January 4, 2016.
Mr. Parini joins Vertex after more than a decade at Pfizer Inc.,
where he served in multiple leadership roles within the company’s
global legal team. Most recently, he served as Senior Vice
President and Associate General Counsel and was responsible for the
strategic management of Pfizer’s global litigation activities,
including civil, intellectual property, government and employment
litigation. Mr. Parini also served as Chief Counsel for multiple
key business units within Pfizer, advising Pfizer’s leadership team
on key business issues related to investment decisions, patent
disputes, global pricing strategies and commercial operations
activities, among other responsibilities.
"Michael brings to Vertex extensive global legal experience
related to the development and commercialization of multiple
medicines,” said Dr. Leiden. “I welcome Michael to the Vertex team
and believe his expertise will be invaluable as we bring our cystic
fibrosis medicines to more people worldwide and advance key
research and development programs across many diseases.”
"I’ve watched Vertex’s evolution over recent years and am
thrilled to join this team at such an exciting and pivotal time in
the company’s history,” said Mr. Parini. “I believe that Vertex is
one of very few companies that has the potential to make a
fundamental change in the treatment of many serious diseases, and I
look forward to joining the team in January.”
Prior to Pfizer, Mr. Parini served as a health care attorney at
Akin, Gump, Strauss, Hauer & Feld, L.L.P. where he provided
legal counsel on federal and state regulatory and policy issues. He
is a member of the New York and District of Columbia bars. He
received a bachelor’s degree in American government from Georgetown
University and his law degree from Georgetown University Law.
About Vertex
Vertex is a global biotechnology company that aims to discover,
develop and commercialize innovative medicines so people with
serious diseases can lead better lives. In addition to our clinical
development programs focused on cystic fibrosis, Vertex has more
than a dozen ongoing research programs aimed at other serious and
life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has
research and development sites and commercial offices in the
United States, Europe, Canada and Australia. For six
years in a row, Science magazine has named Vertex one of
its Top Employers in the life sciences. For additional information
and the latest updates from the company, please
visit www.vrtx.com.
(VRTX-GEN)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151123005292/en/
Vertex Pharmaceuticals IncorporatedInvestors:Michael Partridge,
+1 617-341-6108orEric Rojas, +1
617-961-7205OrMedia:617-341-6992mediainfo@vrtx.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024